Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Patent expiries set to boost flagging French biosimilar market

This article was originally published in Scrip

Executive Summary

Sales of biosimilars in France grew 11-fold between 2008 and 2012, but in value terms the market remains small, with sales of just €60m last year. However, this is set to change as major drugs such as Roche's MabThera (rituximab) and AbbVie's Humira (adalimumab) lose patent protection in the next few years, resulting in an increase in biosimilars' market share and a concomitant decline in the prices of reference drugs, according to a report from the regulatory agency ANSM.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts